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Adenosine 5′-triphosphate is a well-known extracellular signaling molecule and
neurotransmitter known to activate purinergic P2X receptors. Information has been
elucidated about the structure and gating of P2X channels following the determination
of the crystal structure of P2X4 (zebrafish), however, there is still much to discover
regarding the role of this receptor in the central nervous system (CNS). In this
review we provide an overview of what is known about P2X4 expression in the
CNS and discuss evidence for pathophysiological roles in neuroinflammation and
neuropathic pain. Recent advances in the development of pharmacological tools
including selective antagonists (5-BDBD, PSB-12062, BX430) and positive modulators
(ivermectin, avermectins, divalent cations) of P2X4 will be discussed.
Keywords: ATP, P2X4, microglia, pain, antagonist, ivermectin
INTRODUCTION
Purinergic P2X receptors are involved in mediating a multitude of functions in health and
disease via the actions of extracellular adenosine 5′-triphosphate (ATP) (North, 2002; Burnstock
and Kennedy, 2011; Khakh and North, 2012). Although ATP has long been recognized as
an intracellular energy source, its acceptance as an extracellular signaling molecule has taken
considerably longer (Burnstock, 2006). It is now widely recognized that extracellular ATP acts as
either sole neurotransmitter or crucial co-neurotransmitter in most nerves in both the peripheral
nervous system and central nervous system (CNS) (Burnstock, 2006; Khakh and North, 2012).
For example, under physiological conditions, astrocytes and neurons are responsible for releasing
small amounts of ATP, which can then act on purinergic receptors – either P2X ion channels or
P2Y G protein-coupled receptors - expressed on both neurons and glial cells. In healthy tissues,
ATP released from cells is tightly regulated with cell surface ectonucleotidases serving to terminate
purinergic signaling (Cardoso et al., 2015) (this is analogous to the activity of cholinesterases at
cholinergic synapses). However, when released from injured cells, ATP can initiate inflammation
and further amplify and sustain cell-mediated immunity through P2 receptors (Idzko et al., 2014).
P2X receptors are non-selective cation channels that open in response to ATP binding,
allowing the rapid flow of ions (K+, Na+, Ca2+) across the membrane. Seven genes encode
P2X receptor subunits (P2X1-7) that are expressed in all tissues in humans and mice (North,
2002; Khakh and North, 2006). P2X receptors share a common topology assembling as trimers
(Hattori and Gouaux, 2012), with evidence of both homomeric and heteromeric assembly
(Saul et al., 2013). Different subtypes are involved in specialized functions depending on their
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distribution and biophysical properties (Surprenant and North,
2009). These differences provide an opportunity for tissue-
specific inhibition of one subtype without affecting the
function of others. Such challenges represent a pharmacological
opportunity to intervene in physiological processes including
modulation of synaptic transmission, taste, pain sensation, and
inflammation (Khakh and North, 2006).
Progress on several fronts has revealed the involvement of
P2X4 in a variety of pathophysiological processes. For example,
P2X4 are implicated in neuropathic pain (Tsuda et al., 2003,
2009a; Coull et al., 2005; Ulmann et al., 2008), inflammatory
pain (Ulmann et al., 2010), epilepsy (Ulmann et al., 2013), lung
surfactant secretion (Miklavc et al., 2013), alcohol intake and
preference (Wyatt et al., 2014; Franklin et al., 2015), morphine-
induced hyperalgesia (Ferrini et al., 2013), cardiac function
(Yang et al., 2014) and P2X4 deficiency is associated with
sociocommunicative impairments (Wyatt et al., 2013) and altered
flow-dependent blood vessel remodeling (Yamamoto et al., 2006).
However, the study of P2X4 has been seriously hampered by an
absence of selective pharmacological tools. While the discovery of
selective antagonist molecules against P2X4 would facilitate the
further elucidation of their physiological roles, their application
might also hold promises to lead us into novel therapeutics for
human diseases. Here we aim to present a broad, comprehensive
overview of P2X4 receptors, their function in the CNS, and their
emerging pharmacology.
P2X4; ION CHANNEL STRUCTURE AND
PERMEABILITY
The P2X4 receptor, now simply termed P2X4 using the latest
IUPHAR nomenclature (Di Virgilio et al., 2015), is a ligand-gated
ion channel belonging to the P2X receptor family. This family
of ion channels are activated by extracellular ATP and function
as non-selective cation channels permitting Na+, K+ and Ca2+
ion fluxes (North, 2002). The Ca2+ permeability of P2X4 is
the highest among the P2X family (Egan and Khakh, 2004).
Measurement of the fractional calcium current (Pf%) through
P2X4 using the patch clamp photometry technique (measuring
the ATP-induced inward current and the concomitant decrease
in the emission of fura-2 fluorescence excited at 380nm) yields
values of 11% and 15% for rat P2X4 and human P2X4,
respectively (Egan and Khakh, 2004).
P2X subunits are arranged into trimeric structures in
the plasma membrane, either in homomeric or heteromeric
formations (Saul et al., 2013). This trimeric organization of P2X4
was confirmed in 2009 by solving the crystal structure of a
zebrafish P2X4 (zP2X4) in the closed state at 3.1A resolution
(Kawate et al., 2009). Three inter-subunit binding sites for ATP
were defined in the P2X extracellular domain. In 2012 a crystal
structure for the ATP-bound state of zP2X4 was solved revealing
the open pore conformation of the channel (Hattori and Gouaux,
2012). This also gave structural insight into the mechanics
of channel opening in response to ATP binding; fenestrations
open up in close proximity to the plasma membrane providing
lateral access pathways for cation entry to the ion channel
pore (Samways et al., 2011; Hattori and Gouaux, 2012; Gao
et al., 2015). This movement of the extracellular domains upon
agonist binding leads to iris-like rotational movements of the
transmembrane domains lining the channel pore thus describing
the predicted activation mechanism of P2X4 channels (Hattori
and Gouaux, 2012). Fast-scanning atomic force microscopy has
also been used to reveal the trimeric structure of P2X4 and
movement of subunits following ATP binding (Shinozaki et al.,
2009).
The P2X4 subtype can heteromerically assemble with other
P2X members including P2X6, P2X7 and P2X1 (Le et al.,
1998; Nicke et al., 2005; Antonio et al., 2011). These studies
have typically used immunoprecipitation of P2X4-containing
protein complexes and detection of other P2X using antibodies
in combination with altered functional and pharmacological
properties as major pieces of experimental evidence. For example,
Xenopus oocytes expressing both P2X1 and P2X4 exhibit a slowly
desensitizing current similar to homomeric P2X4 but in the
presence of P2X1 there is significant activation by αβ-MeATP
and inhibition by suramin (Nicke et al., 2005), properties not
seen with either P2X4 or P2X1 alone. The reported interaction
with P2X7 is much more contentious. Evidence first suggested
that P2X4 and P2X7 could form heterotrimeric complexes
(Boumechache et al., 2009) but then further investigations
revealed that homotrimers of P2X4 and P2X7 may interact with
each other (Antonio et al., 2011).
PERMEABILITY
Khakh and colleagues first described different permeability states
for P2X4, denoting two states (I1 and I2 state) in response to a
sustained exposure to ATP (Khakh et al., 1999a). This secondary
permeability state (I2) displays increased NMDG+ permeation
suggestive of a larger channel pore size and a dynamic change
in ion selectivity. This concept has recently been challenged and
Vrev changes recorded during NMDG+/Na+ bi-ionic conditions
is thought to be due to alterations in intracellular ion depletion
and accumulation (Li et al., 2015). This data can be interpreted
as lack of evidence for dynamic changes in ion conductance but
whether P2X channels are directly permeable to large cations
such as NMDG+ still warrants further investigation. Further
evidence for a secondary permeability state (or permeation of
large organic cations) for P2X4 comes from the use of membrane
impermeant fluorescent dyes such as YOPRO-1 iodide and
ethidium bromide (Khakh et al., 1999a; Bernier et al., 2012).
Whether these dyes permeate directly through the P2X4 channel
or an associated conduit is not yet clear. Much evidence exists
for a large secondary permeation pathway activated by P2X7 in
numerous cell types. Classically this is measured by the use of dye
uptake assays (in particular such as ethidium bromide, YOPRO-
1 iodide, Lucifer yellow). Controversy surrounds the underlying
mechanism of action for P2X7 with some studies suggesting a
second protein may carry the dyes, such as pannexin-1 (Pelegrin
and Surprenant, 2006) or anoctamin-6 (Ousingsawat et al., 2015)
and others suggesting that P2X7 itself can allow passage of large
molecules (Browne et al., 2013). The physiological role of this
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permeability pathway for large cations is still unclear for P2X7
and P2X4 channels, and indeed those other ligand-gated ion
channels demonstrating a similar phenomenon (Chung et al.,
2008; Banke et al., 2010).
EXPRESSION OF P2X4 IN THE CNS
P2X4 was originally cloned from rat brain cDNA in 1996 (Soto
et al., 1996a) and was the first P2X receptor detected in CNS
neurons and blood vessels. P2X4 was subsequently cloned from
a human brain sample (Garcia-Guzman et al., 1997) and was
also found to exhibit a broad tissue expression pattern. Amongst
the P2X receptor subtypes, P2X4, along with P2X2 and P2X6,
has been shown to be the most widespread and abundantly
expressed functional ATP-gated purinergic receptor in the CNS,
being found in most neurons and glial cells (Buell et al., 1996; Soto
et al., 1996a,b; Tsuda et al., 2003; Guo et al., 2005; Amadio et al.,
2007; Vazquez-Villoldo et al., 2014). This has been illustrated
at both mRNA and protein level by in situ hybridisation,
immunohistochemistry, PCR and immunoblotting (Soto et al.,
1996b; Lê et al., 1998; Bo et al., 2003).
NEURONS
Throughout the CNS, expression of P2X4 is widely observed
in neurons. In the original paper cloning P2X4 from rat brain,
Soto and colleagues demonstrated high levels of P2X4 mRNA
in rat dentate gyrus granule cells, CA1/CA3 pyramidal cells,
cerebellar cortex Purkinje cells, and neurons of the pontine
nucleus (Soto et al., 1996a). Electron microscopy analysis suggests
P2X4 localisation in peri-synaptic regions of post-synaptic
terminals and on pre-synaptic terminals (Rubio and Soto, 2001).
Immunohistochemistry also shows P2X4 to be expressed in
GABAergic interneurons and GABAergic spiny neurons of the
rat striatum and substantia nigra (Amadio et al., 2007).
The hypothalamus and anterior pituitary gland abundantly
express P2X4 and this receptor may be involved in regulation
of hypothalamo-pituitary functions in the CNS, as reviewed
in Stojilkovic (2009). Immunohistochemistry studies identified
P2X4 on paraventricular nucleus neurons projecting to the
rostral ventrolateral medulla and a potential role in regulating
sympathetic nerve activity (Cham et al., 2006). Paraventricular
neurons, arcuate nucleus GnRH neurons and secretory cells
of the anterior pituitary all express P2X4 as illustrated
through molecular biology techniques in combination with
electrophysiology (Zemkova et al., 2010). Functional P2X4
receptors have also been identified in lactotrophs (He et al.,
2003), and in the posterior pituitary system functional P2X4
responses have been recorded from supraoptic neurons (Vavra
et al., 2011; Stojilkovic and Zemkova, 2013). P2X4 has also been
demonstrated to be expressed in somatosensory cortical neurons
(Lalo et al., 2007), nodose ganglion neurons (Tan et al., 2009),
trigeminal neurons (Luo et al., 2006), vestibular ganglion neurons
(Ito et al., 2010), retinal ganglion and bipolar cells (Wheeler-
Schilling et al., 2001) and in spinal cord neurons (Bardoni et al.,
1997; Kobayashi et al., 2005).
P2X4 has been implicated in physiological functions in the
CNS including modulation of neurotransmission and synaptic
strengthening (Rubio and Soto, 2001; Sim et al., 2006; Baxter
et al., 2011). In the hippocampus P2X4 expression on pyramidal
neurons is thought to contribute to synaptic plasticity and long-
term potentiation (LTP). One of the initial studies that elaborated
a role for P2X4 in LTP was performed in mice with a global
deficiency in the p2rx4 gene (P2X4−/−) (Sim et al., 2006).
Extracellular recording of field potentials from the CA1 region of
the hippocampus in these P2X4-deficient mice revealed reduced
synaptic facilitation and induction of LTP compared to wild-
type counterparts. In addition, ivermectin, a positive allosteric
modulator of P2X4, increased LTP in wild-type mice but was
ineffective in the P2X4−/− mice (Sim et al., 2006). This suggested
that P2X4 contributes to strengthened synaptic activity during
LTP and it is hypothesized that calcium entry through sub-
synaptic P2X4 contributes to synaptic strengthening by NMDA
receptor incorporation (Baxter et al., 2011).
Studies have also investigated cross-talk between P2X4 and
other ion channels in neurons, in particular GABA(A) receptors
(Jo et al., 2011) and nicotinic acetylcholine receptors (Khakh
et al., 2000). In hypothalamic neurons increased expression of
P2X4 is associated with a reduction in GABAergic currents
(Jo et al., 2011). There is some evidence for a physical coupling
between P2X4 and GABA(A) receptors and this may play a role
in regulating synaptic signaling (Jo et al., 2011). A similar cross-
talk has been demonstrated for P2X2 receptors and GABA(A)
receptors and this cross-talk appears to be a general mechanism
for the regulation of GABAergic signaling, as reviewed in
Shrivastava et al. (2011). Therefore, P2X4 may be involved
in regulating excitatory vs. inhibitory neurotransmission in
neurons, acting as a neuromodulator. The contribution of P2X4
in this process will likely become clearer in the future with
the development of selective pharmacological tools and more
knockout mouse studies.
GLIAL CELLS
In the CNS P2X4 plays a role in modulating synaptic transmission
and communication between neurons and neighboring glial cells.
Glia are the most abundant cell type accounting for >70% of
total cells in the CNS and can be classified into three main types;
astrocytes, oligodendrocytes and microglia.
The role of P2X4 in microglial cells has received much
attention in the last decade. Microglial cells, known as the
resident macrophages in the CNS, originate from the yolk sac
and are related to myeloid immune cells (Kettenmann et al.,
2011; Saijo and Glass, 2011). Immunohistochemistry analysis
has revealed abundant P2X4 reactivity on microglia within
the brain and spinal cord (Tsuda et al., 2003; Ulmann et al.,
2008). Despite the fact that P2X4 is abundantly expressed in
microglial cells, the majority of labeled P2X4 appears to be
predominantly localized to intracellular lysosomal compartments
(Qureshi et al., 2007; Toyomitsu et al., 2012). P2X4 has been
suggested to play a role in regulating the activation and migration
of microglial cells at sites of injury (Guo et al., 2005; Schwab
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et al., 2005). Following peripheral nerve injury, the expression
of P2X4 is up-regulated in activated spinal cord microglia at
the transcriptional, translational and post-translational levels
(Ulmann et al., 2008). Several factors that have been associated
with regulating P2X4 expression include the chemokine CCL21
(Biber et al., 2011), fibronectin (Nasu-Tada et al., 2006; Tsuda
et al., 2008), and the cytokine interferon gamma (IFN-γ) (Tsuda
et al., 2009b), while activation of the chemokine receptor CCR2
is a key factor involved in post-translational regulation of
P2X4 (Toyomitsu et al., 2012). Fibronectin and IFN-γ can
regulate P2X4 expression through the IRF5 transcription factor
in microglia (Masuda et al., 2014).
P2X4 activation in spinal microglia leads to the release of
brain-derived neurotrophic factor (BDNF), which communicates
between microglia and spinal interneurons resulting in pain
hypersensitivity via disinhibition of GABAergic input (Tsuda
et al., 2003; Coull et al., 2005; Ulmann et al., 2008; Trang et al.,
2009). Allodynia induced through peripheral nerve injury was
reversed by pharmacological blockade of P2X4 receptors in the
spinal cord (Tsuda et al., 2003) and P2X4−/− mouse models
have reduced inflammatory and neuropathic pain (Ulmann
et al., 2008). These findings highlight the importance of P2X4
in microglial cells in the development of neuropathic pain, as
reviewed by Inoue and Tsuda (2012) and Tsuda et al. (2013)
and summarized in Figure 1. Furthermore, activated microglia
play a critical role in the pathogenesis of other diseases such
as spinal cord injury, stroke and neurodegenerative disease (i.e.,
Alzheimer’s and Parkinson’s disease), therefore P2X4 may also
contribute to pathogenesis of these conditions.
Astrocytes are star-shaped glial cells providing a wide variety
of functional support for neurons. P2X1-5 and P2X7 receptors
have been identified at the transcriptional level in situ and
in vitro in primary cultured rat cortical astrocytes, hippocampal
astrocytes and astrocytes in the nucleus accumbens (Franke
et al., 2001; Fumagalli et al., 2003; Dixon et al., 2004) and
protein expression was further confirmed (Kukley et al., 2001).
In rat hippocampus, immunostaining revealed expression of
P2X4 particularly in S100β positive astrocytes in the CA1, CA3
and dentate gyrus regions (Kukley et al., 2001). However, in
acutely isolated mouse cortical astrocytes no mRNA expression
for P2X4 was detected using qRT-PCR. This correlated with
electrophysiology studies showing insensitivity of ATP-induced
currents to the positive modulator ivermectin (Jabs et al., 2007).
At a functional level, P2X4 responses are not ubiquitously found
since P2X4-mediated currents were not detected in acutely
isolated cortical astrocytes (Lalo et al., 2008) or hippocampal
slices (Jabs et al., 2007). Currently, therefore, there is limited
evidence for P2X4 in astrocytes.
Oligodendrocytes are glial cells primarily responsible for
myelination of neurons in the CNS and expression of several
types of P2 receptor including P2X4 has been demonstrated in
oligodendrocytes and in oligodendrocyte precursor cells (OPCs)
(Agresti et al., 2005). Aside from neurons and neuroglial cells
there is a vast network of blood vessels in the CNS. There is a long
standing interest in the role of P2X4 in peripheral endothelial
cells and the regulation of blood vessel tone (Yamamoto et al.,
2000, 2006). P2X4 is abundantly expressed in peripheral vessel
endothelial cells but it is unclear if this is also true for brain
microvascular endothelial cells which play an important role in
constitution of the blood brain barrier (BBB) and deterioration
of this barrier is implicated in several neurological disorders.
To date expression of P2X4 has been demonstrated in the
hCMEC/D3 human microvascular endothelial cell line and the
mouse microvascular cell line bend.3 (Bintig et al., 2012; Ozaki
et al., 2016). Similar to the periphery, brain endothelial P2X4
may be involved in regulating shear stress responses in the
cerebral vasculature and stimulation of protective factors such as
osteopontin to enable ischaemic tolerance (Ozaki et al., 2016).
SUBCELLULAR LOCALISATION OF P2X4
The cellular localisation of most P2X receptors is thought to
be predominantly at the plasma membrane. However, P2X4
expression at the cell surface is limited with the majority
of receptors occupying an intracellular residency in resting
cells (Robinson and Murrell-Lagnado, 2013). P2X4 contains
an additional C-terminal trafficking motif (YxxxGϕ) which
FIGURE 1 | Postulated role of P2X4 signaling in chronic pain. Peripheral nerve injury (PNI) activates microglia in the dorsal horn of the spinal cord. This causes
the upregulation of the P2X4 expression which is modulated by fibronectin and chemokine ligand 21 (CCL21). CCL2 signaling promotes P2X4 trafficking to cell
surface of microglia. Influx of Ca2+ through ATP-stimulated P2X4 activates p38-MAPK and drives the synthesis and SNARE-dependent release of brain-derived
neurotrophic factor (BDNF). After BDNF is released, it acts on its cognate receptor, trkB which consequently downregulates potassium-chloride cotransporter KCC2
expression in dorsal horn spinal lamina 1 neurons. This results in increase of intracellular [CI−] and leads to the reduction in anion gradient in dorsal horn which in
turn induces depolarization of these neurons. The altered chloride gradient causes GABA to switch its effects from inhibition to excitation. The resultant
hyperexcitability in the dorsal horn could underlie the increased sensitivity that is a feature of neuropathic pain.
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facilitates rapid internalization of cell surface P2X4 via AP2
and clathrin-dependent endocytosis (Royle et al., 2005). The
subcellular distribution of P2X4 in many cell types shows a
punctate, clustered staining pattern with overlapping markers
of intracellular vesicles including recycling endosomes and
lysosomes (Bobanovic et al., 2002; Qureshi et al., 2007; Stokes
and Surprenant, 2009). Although regulated trafficking is not
unique to P2X4 among the P2X receptor family, the ability
of P2X4 to rapidly recycle between the plasma membrane
and intracellular compartments is a robust feature studied
by electrophysiological and biochemical methods. There is
strong evidence that P2X4 receptors localize to the plasma
membrane, endosomes, lysosomes, and vacuoles. Insights about
dynamic P2X4 trafficking were revealed with use of a pH-
sensitivecou fluorescent protein, pHluorin. Khakh and colleagues
have recently used P2X4-pHluorin for in vitro trafficking studies
to quantify and track P2X4 distribution within subcellular
compartments (Xu et al., 2014). Similarly, other mechanistic
studies also showed that P2X4 upregulation occurs both via
altered trafficking and via increased P2X4 gene expression
(Toulme et al., 2006, 2010; Raouf et al., 2007; Toulme and Khakh,
2012). Recently it was suggested that P2X4 functions as an ATP-
gated channel in lysosomes (Huang et al., 2014) and regulates
endolysosomal membrane fusion via Ca2+-dependent activation
of calmodulin (Cao et al., 2015).
P2X4 DOWNSTREAM SIGNALING
PATHWAYS
Following ATP activation of P2X4 channels in the plasma
membrane, the rapid influx of cations (Na+ and Ca2+) will cause
membrane depolarisation. In addition the significant influx of
Ca2+, as has been reported for P2X4, will likely trigger important
downstream signaling pathways. For example, Ca2+ is important
in neurons in the regulation of neurotransmitter release (Neher
and Sakaba, 2008) and in various microglial functions (Farber
and Kettenmann, 2006).
Recently, several lines of evidence suggest that P2X4
stimulated microglia signal to spinal lamina I dorsal horn
neurons causing nociceptive output and that the critical
microglia-neuron signaling molecule is BDNF (Coull et al.,
2005). Notably, accumulation of BDNF in spinal dorsal horn
microglia following nerve injury in global P2X4−/− mice showed
impaired ATP-evoked BDNF release which further demonstrated
that P2X4 plays an important role in controlling BDNF release
from microglia (Ulmann et al., 2008). The mechanistic gap
between the activation of P2X4 and release of BDNF from
microglia was bridged with a study from Salter and colleagues
(Trang et al., 2009). Influx of Ca2+ through P2X4 in cultured
microglia is a critical intracellular step linking stimulation
of these receptors to the activation of p38 MAPK. This
implicates p38 MAPK activation and BDNF release as a key
step in microglia-neuron communication leading to nerve injury
induced pain hypersensitivity. However, there may be other cell
types expressing P2X4 involved in pain pathways. Peripheral
macrophages also express P2X4 triggering Ca2+ influx and p38
MAPK phosphorylation (Ulmann et al., 2010). This signaling
could further activate cytosolic PLA2 liberating arachidonic acid
(AA) and release of prostaglandin E2 (PGE2). Consequently, the
release of PGE2 leads to hypersensitivity of peripheral nociceptive
pathways which is a hallmark of inflammatory pain (Basbaum
et al., 2009).
P2X4 IN CNS DISORDERS
As knowledge regarding the expression and the characteristics of
the individual P2X channels has emerged and expanded since
they were first cloned in the late 1990s, questions have arisen
over the importance of P2X channels in normal physiological
functioning and their functioning in pathological conditions.
Information regarding the specific role of P2X4 has been slower
to accumulate largely due to the lack of selective antagonists
for this P2X subtype (see P2X4 pharmacology section below).
The first evidence for a pathological role for P2X4 was in
pain processing. A landmark study by Tsuda and colleagues
used antisense P2X4 oligonucleotides and described a major
role for P2X4 in chronic pain and mechanical allodynia (Tsuda
et al., 2003). The development of transgenic mice lacking P2X4
expression has since confirmed the role of this ion channel in
modulation of pain signaling (Ulmann et al., 2008, 2010; Tsuda
et al., 2009a).
CHRONIC PAIN
Chronic pain is described as persistent pain arising from a
modification of pain processing pathways in the spinal cord and
can be labeled as allodynia, hypersensitivity or neuropathic pain
(Basbaum et al., 2009; Cohen and Mao, 2014). There are several
review articles describing purinergic receptors in the context of
pain and it is important to acknowledge here that more than
one purinergic receptor has been implicated in pain – currently
P2X2/3, P2X7 and P2Y1, P2Y2, P2Y12 are thought to be involved
in the modulation of pain processing (Jarvis, 2010; Tsuda, 2016).
Tsuda and colleagues demonstrated that P2X4 was
upregulated in spinal microglia after nerve injury (ligation
of the fifth lumbar spinal nerve) and mediated tactile allodynia
(defined as a hypersensitivity to non-painful stimuli) (Tsuda
et al., 2003). Blocking P2X4 (with TNP-ATP) or knocking down
P2X4 with antisense oligonucleotides reversed the allodynia
phenotype and thus suggested that P2X4 may be a potential
therapeutic target for this type of neuropathic pain. In 2005
it was demonstrated that communication between microglia
and neurons was essential for the development of allodynia
and that the critical factor involved was BDNF (Coull et al.,
2005). Stimulation of spinal microglia with ATP induced
BDNF secretion which through activation of TrkB receptors
on spinal output neurons, alters Eanion causing disinhibition of
GABAergic inputs from inhibitory spinal neurons. This leads
to hyperexcitability of output neurons in the pain pathway.
BDNF was already known to be a pro-nociceptive factor able
to sensitize neurons (Kerr et al., 1999) but this study was the
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first to connect ATP-P2X4-BDNF to the neuronal shift in Eanion.
Ulmann et al. (2008) then provided direct evidence for P2X4 in
mediating BDNF secretion from spinal microglia using a P2X4-
deficient mouse generated by the Rassendren lab. They further
demonstrated that P2X4−/− mice did not develop mechanical
hyperalgesia following peripheral nerve injury. This lack of
mechanical hyperalgesia was confirmed using a second global
P2X4 deficient mouse generated by the Ando lab. Behavioral
tests demonstrated no difference in acute thermal, mechanical
and chemical induced pain sensing in these P2X4−/− mice but
there was significant suppression of chronic inflammatory pain
(induced by CFA injection) and allodynia due to nerve injury
(Tsuda et al., 2009a).
More recently, P2X4 has been implicated in tolerance
to morphine (Horvath et al., 2010) and morphine-induced
hyperalgesia (Ferrini et al., 2013). Morphine enhanced microglial
migration in vitro in a µ-opioid receptor dependent manner,
and antisense P2X4 oligonucleotides reduced the development of
morphine tolerance in rats (Horvath and DeLeo, 2009; Horvath
et al., 2010). Furthermore, Ferrini et al. (2013) demonstrated
morphine hyperalgesia required µ-opioid receptor-mediated
upregulation of P2X4 in spinal microglia. Blocking the BDNF-
TrkB pathway reversed the hyperalgesia. Therefore the microglial
ATP-P2X4-BDNF axis seems to be a central pathway involved
in the setting of pain thresholds. However, recent evidence has
revealed that this mechanism may be restricted to males since
female rodents did not display upregulation of P2X4 on microglia
(Sorge et al., 2015; Mapplebeck et al., 2016).
ALCOHOL-RELATED DISORDERS
In the search to identify therapeutic targets for Alcohol Use
Disorders (AUD), several studies have demonstrated that P2X4
plays a role in alcohol-induced behavior (Yardley et al., 2012;
Wyatt et al., 2014). P2X4 are expressed in key brain regions
implicated in the reinforcing properties of alcohol and other
drugs (Kimpel et al., 2007). This supports a role for P2X4
in alcohol addiction probably via modulation of P2X4 in
the mesolimbic dopamine system, the brain reward system
(Khoja et al., 2016). In vitro, P2X4 are inhibited by ethanol
concentrations as low as 5mM and ethanol is thought to block
the P2X4 channel in the open state but does not affect channel
deactivation (Davies et al., 2005; Ostrovskaya et al., 2011). Crucial
residues that mediates ethanol effects on P2X4 gating are Trp46,
His241, Asp331 and Met336 (Xiong et al., 2005; Popova et al.,
2010, 2013).
In P2X4−/− mice heightened ethanol intake behavior is
observed over wild-type counterparts suggesting that the P2X4
gene may be linked with alcohol intake and/or preference
(Asatryan et al., 2011; Franklin et al., 2014). It has been shown
that alcohol-preferring rats have lower expression of the P2X4
gene than alcohol-non-preferring rats, suggesting a correlation
between P2X4 expression and alcohol intake (Kimpel et al., 2007;
Franklin et al., 2015). Ivermectin, a broad-spectrum antiparasitic
used worldwide in humans and animals, can antagonize the
inhibitory action of ethanol on P2X4 and is suggested to interfere
with ethanol binding to the channel (Asatryan et al., 2010). Other
avermectins have been demonstrated to act in a similar fashion
(Asatryan et al., 2014; Huynh et al., 2017). Studies also identify
a role for P2X4 in regulating dopaminergic neurotransmission
within the mesolimbic system. In dopaminergic neurons of
the mesolimbic system, P2X4 has been shown to play a role
in mediating alcohol-drinking behavior (Franklin et al., 2015).
P2X4 receptor activity has also been linked to other behaviors
of associated with dopaminergic neurotransmission, including
motor control and sensorimotor gating (Khoja et al., 2016).
Overall, these findings suggest that alcohol intake may be
modulated by ethanol acting on P2X4 and that pharmacological
potentiation of P2X4 by ivermectin or avermectin analogs may
reduce alcohol consumption and preference.
NEUROINFLAMMATORY DISORDERS
Neuroinflammation describes inflammatory changes in the brain
and spinal cord associated with activation of the immune system
(DiSabato et al., 2016). This is thought to be mediated by
mediators such as chemokines, cytokines and second messengers
(such as nitric oxide and prostaglandins). Resident immune
cells such as microglia are involved, as are endothelial cells
and astrocytes. Microglia regulate cytokines and inflammatory
processes in the brain, typically elevated pro-inflammatory
cytokines (IL-6, TNF-α, and IL-1β) and chemokines (CCL2,
CCL5, CXCL1) define a state of neuroinflammation, as reviewed
in DiSabato et al. (2016).
Neurodegenerative diseases such as Alzheimer’s disease and
Parkinson’s disease are associated with neuroinflammation
(Ransohoff, 2016) and microglia appear to be central (Saijo and
Glass, 2011; Joers et al., 2016; Wes et al., 2016). P2X4 and
the related purinergic channel P2X7 (Bhattacharya and Biber,
2016) are involved in the regulation of microglial pathways
therefore may also play roles in exacerbating inflammation in
the CNS. P2X4−/− mice (Rassendren mouse model) have an
attenuated inflammatory response associated with spinal cord
injury with reduced NLRP1 inflammasome-related signaling
pathways (de Rivero Vaccari et al., 2012). P2X4 deficiency also
reduced the infiltration of peripheral immune cells (neutrophils
and macrophages) to the spinal cord (de Rivero Vaccari et al.,
2012).
P2X4 was up-regulated in microglial cells in an animal
model of multiple sclerosis (autoimmune EAE in rats) (Vazquez-
Villoldo et al., 2014). Using LPS as a model of neuroinflammation
the P2X4 antagonists TNP-ATP and 5-BDBD were shown to
reduce microglial activation in vivo and reduce the microglial
loss in spinal cord. Following i.c.v. injection of LPS, the dentate
gyrus region of the hippocampus showed classical hallmarks of
microglial activation which were blocked by TNP-ATP (Vazquez-
Villoldo et al., 2014).
Alcohol abuse is thought to enhance neuroinflammation
(Potula et al., 2006) and the P2X4 receptor on microglial cells
has been implicated (Gofman et al., 2014, 2016). In addition
neuroinflammatory responses are also associated with ischaemic
events in the brain and studies demonstrate upregulation of P2X4
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in microglia following hypoxia and ischaemia (Wixey et al., 2009;
Li et al., 2011). Recently, using a mouse model of middle cerebral
artery occlusion (MCAO) endothelial P2X4 was required for the
neuroprotective effect of ischaemic preconditioning (transient
ischaemia followed by reperfusion) (Ozaki et al., 2016). P2X4 is
known to be activated by shear stress generated by conditions
of flow in peripheral endothelial cells (Yamamoto et al., 2000,
2006). Mice with a conditional knockout of vascular endothelial
P2X4 showed severe deficits after MCAO due to an attenuation
in release of the neuroprotective factor osteopontin (Ozaki et al.,
2016).
P2X4 PHARMACOLOGY
There has been significant progress in understanding P2X
receptor pharmacology in recent years. Despite such advances,
there remains a paucity of potent and selective pharmacological
tools for some receptors. Agonists that selectively activate distinct
members of this family are elusive, and with a few exceptions,
progress has been slow when identifying selective inhibitors,
some of which are shown in Figure 2. Here we describe what is
currently known regarding pharmacological modulators of P2X4.
AGONISTS
The most potent agonist of homomeric P2X4 is ATP. Dose-
responses for ATP at rat and human P2X4 gave EC50 values of
6.9 ± 0.8 and 7.4 ± 0.5 µM, respectively (Soto et al., 1996a;
Garcia-Guzman et al., 1997). In the original article characterizing
rat P2X4 expressed in Xenopus oocytes the electrophysiological
profile of agonists was ATP > 2-methylthio-ATP > CTP > α, β-
methylene-ATP > dATP and no response was elicited by ADP,
AMP, GTP, adenosine or the β,γ-methylene-ATP analog (Soto
et al., 1996a). For human P2X4 expressed in Xenopus oocytes the
same order of efficacy was demonstrated (Garcia-Guzman et al.,
1997). BzATP is also known to act as a partial agonist at rat and
human P2X4 (Bowler et al., 2003; Stokes et al., 2011).
POSITIVE MODULATORS
One of the most distinguishing features of P2X4 is potentiation
by ivermectin – a macrocyclic lactone derived from the selective
hydrogenation of avermectin B1, a natural product synthesized
by Streptomyces avermitilis. Ivermectin is a mixture of 22,23-
dihydroavermectin B1a and B1b in an approximate 80:20 ratio
(Laing et al., 2017). Use of ivermectin as a successful anti-
helminthic drug is due to its positive allosteric modulation
of glutamate–gated chloride channels in nematode worms.
Ivermectin also potentiates responses at vertebrate GABA(A) and
nicotinic α7 receptors (Kru˚šek and Zemková, 1994; Krause et al.,
1998). Of all purinergic receptors, P2X4 is the most sensitive to
ivermectin (Khakh et al., 1999b) although a recent report claims
some potentiation of human P2X7 responses by ivermectin
(Nörenberg et al., 2012). Extracellular, but not intracellular,
application of ivermectin (≤10 µM) potentiates P2X4 currents
and delays channel deactivation (Khakh et al., 1999b; Priel and
Silberberg, 2004). These observations are likely the result of
ivermectin binding to separate sites on P2X4, a high affinity
ivermectin binding site (pEC50 6.6) which increases maximal
current activated by saturating concentrations of ATP, and a
low affinity site (pEC50 5.7) which slows channel deactivation
(Priel and Silberberg, 2004). Ivermectin appears to interact with
the transmembrane domains of P2X4 and lateral fenestrations
(Jelinkova et al., 2006; Silberberg et al., 2007; Hattori and Gouaux,
2012; Samways et al., 2012; Rokic et al., 2013) including a binding
pocket which overlaps with an inhibitory ethanol binding site
(Asatryan et al., 2010).
Avermectin analogs in addition to ivermectin also have
positive modulator activity at P2X4. These include avermectin,
emamectin, doramectin (Silberberg et al., 2007) and more
recently abamectin, selamectin, and moxidectin (Asatryan et al.,
2014; Huynh et al., 2017). Of these avermectin, abamectin and
moxidectin have similar effects to ivermectin in preventing the
action of ethanol on P2X4, but have less effect on GABA(A)
receptors (Asatryan et al., 2014; Huynh et al., 2017).
There is also evidence for positive allosteric modulation of
P2X4 by cibacron blue, an isomer of reactive blue-2, in functional
studies. Potentiation of P2X4 responses were attributable to an
increase in the apparent affinity of ATP for the rat P2X4 (Miller
et al., 1998). This potentiation of P2X4 responses is smaller than
that of ivermectin and was not demonstrated in cells expressing
human P2X4 (Garcia-Guzman et al., 1997).
BROAD SPECTRUM PURINERGIC
RECEPTOR ANTAGONISTS
P2X4 receptors are generally less sensitive to the broad
P2X antagonists, such as suramin and pyridoxalphosphate-6-
azophenyl-2′,4′-disulfonic acid (PPADS). Suramin shows very
weak activity at mouse, rat and human P2X4 orthologs with
maximal inhibition of P2X4 currents ranging between 11 and
35% with pIC50 > 4 for all orthologs (Jones et al., 2000). In
contrast, PPADS fully inhibits human and mouse P2X4 (pIC50
∼ 5 for both), whilst the rat receptor is relatively insensitive
to PPADS (Jones et al., 2000). It has been hypothesized that
PPADS acts, in part, by forming a Schiff base with a lysine
residue in P2X1 and P2X2. However, this residue in the P2X4
is replaced by a glutamate at the analogous position (Glu249)
and when it is replaced by a lysine, the resultant P2X4 mutant
is sensitive to inhibition by PPADS. Notably, the human P2X4
has only one lysine (Lys127), which is absent in the rat P2X4,
conferring sensitivity to PPADS, and mutation of the residue to
a lysine in the rat P2X4 (Asn127Lys) did not produce a PPADS-
sensitive channel (Buell et al., 1996). Critically, the increased
sensitivity of the human P2X4 to PPADS inhibition might not
be only due to the different ability of PPADS to form Schiff base
via lysine residues. In addition, several studies have confirmed
that 2′,3′-O-(2,4,6-trinitrophenyl) ATP (TNP-ATP), which is a
potent antagonist at P2X1, P2X3 and P2X2/3 receptors, acts as
a weakly effective antagonist (IC50 15.2 µM) at P2X4 receptors
(Virginio et al., 1998). TNP-ATP is a competitive antagonist at
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FIGURE 2 | Chemical structures of P2X4 antagonists.
P2X4 and can displace [35S]ATPγ S binding to human P2X4
(Hernandez-Olmos et al., 2012; Abdelrahman et al., 2016). The
potency of TNP-ATP at P2X4 estimated by Ca2+ influx assays
in 1321N1 astrocytoma cells was 1.46–4.22 µM dependent on
species (Abdelrahman et al., 2016).
DIVALENT CATIONS AND pH
With regard to ions, P2X4 is amongst the most sensitive P2
receptor to potentiation by zinc ions (Zn2+). Low concentrations
(1–5 µM) of extracellular Zn2+ increases the gating efficiency
of human or rat P2X4 without affecting the maximal response,
however, high (>100 µM) extracellular Zn2+ inhibits P2X4
currents in a voltage-dependent fashion (Garcia-Guzman et al.,
1997; Wildman et al., 1999; Acuna-Castillo et al., 2000). Similarly,
the potentiating effects of Zn2+ are mimicked by Cd2+, however,
Cu2+ modifies P2X4 activity in the opposite direction causing
inhibition (Acuna-Castillo et al., 2000; Coddou et al., 2005).
High concentrations of extracellular Cu2+ (300 µM) inhibit rat
P2X4 in a non-competitive and voltage-independent fashion and
this effect can be seen with other metal cations such as Hg2+
(Coddou et al., 2005). His140 plays a crucial role in the inhibitory
action of Cu2+ but this was not required for the action of Zn2+
at P2X4 (Coddou et al., 2003). Moreover, Asp138 was further
identified as important for Cu2+ binding at P2X4 and Cys132
was critical for Zn2+ potentiation at P2X4 (Coddou et al., 2007).
These residues were validated by an NMR resolved structure of
rat P2X4 extracellular domain as key residues that coordinate
Cu2+ binding (Igawa et al., 2015).
The activity of P2X4 is not only regulated by metals and
ions, but is also modulated by extracellular H+, such that
pH < 6 completely inhibits channel activity and responses are
potentiated above physiological pH (Wildman et al., 1999; Clarke
et al., 2000). One key residue, His286, has been identified in
conveying pH-sensitivity to P2X4 (Clarke et al., 2000). Inhibition
by low pH may be an important physiological regulator of
P2X4 receptor since P2X4 displays a predominant lysosomal
distribution (Qureshi et al., 2007) where it appears to function
as a lysosomal ion channel in addition to its plasma membrane
role (Huang et al., 2014). In lysosomes the luminal pH is typically
acidic with a resting pH 4.6 maintained by vacuolar H+-ATPases.
Under these conditions P2X4 was not active but following
alkalinisation of lysosomes with NH4Cl, ATP-induced responses
could be recorded (Huang et al., 2014).
ANTIDEPRESSANTS
Recent studies have documented that some antidepressants
may inhibit P2X4 receptors, however, this evidence remains
controversial in view of contrasting findings. P2X4 is inhibited
by several clinically used antidepressants including paroxetine,
fluoxetine, desipramine, fluvoxamine, nortriptyline, and
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TABLE 1 | P2X4 modulators and antagonists.
Compound Nature Potency at P2X4 IC50 µM (species) Selectivity Reference
5-BDBD Competitive 1.6 (Human) Not reported Balazs et al., 2013;
Abdelrahman et al., 2016
PSB-12054 Allosteric 0.189 (Human) 30-fold (P2X1) Hernandez-Olmos et al., 2012
2.10 (Rat) 50-fold (P2X2, 3, 7)
1.77 (Mouse)
PSB-12062 Allosteric 1.38 (Human) 35-fold (P2X1-3, 7) Hernandez-Olmos et al., 2012
0.928 (Rat)
1.76 (Mouse)
BX-430 Non-competitive allosteric 0.54 (Human) 10-fold (P2X1-3, 5) Ase et al., 2015
100-fold (P2X7)
1.89 (Zebrafish)
Carbamazepine derivative Negative allosteric modulator 3.44 (Human) 2-fold (P2X1, 3) Tian et al., 2014
30-fold (P2X2, 7)
54.6 (Rat)
14.9 (Mouse)
NP-1815-PX Not reported 0.26 (Human) Not reported Matsumura et al., 2016
Ivermectin Positive allosteric modulator 0.25 (Human) Acts on human P2X7 Priel and Silberberg, 2004;
Nörenberg et al., 2012
Cibacron blue Potentiator Not determined Not reported Miller et al., 1998
clomipramine (Nagata et al., 2009). Of these paroxetine is
the most potent, non-competitively inhibiting human P2X4
heterologously expressed in 1321N1 cells at a pIC50 of 5.7
(Nagata et al., 2009; Abdelrahman et al., 2016). The studies
suggest that such compounds may mediate analgesic effects in
neuropathic pain models via the inhibition of P2X4 (Nagata
et al., 2009; Zarei et al., 2014; Yamashita et al., 2016). However,
paroxetine is much more potent as a serotonin reuptake
inhibitor than an inhibitor of P2X4. There is also evidence that
antidepressants may affect lysosomal trafficking of P2X4 in
cerebellar microglial cells (Toulme et al., 2010). Furthermore,
the hypothesis that the widely used tricyclic antidepressant
amitriptyline may exert analgesic effects through P2X4 inhibition
has also been tested (Sim and North, 2010). Amitriptyline applied
acutely at 10 µM or by pre-incubation for several hours, had no
effect on human P2X4 channel activity though modest inhibitory
effects of 10 µM amitriptyline were observed at mouse and rat
P2X4 (Sim and North, 2010). It is therefore highly unlikely that
amitriptyline mediates analgesic effects via P2X4 inhibition in
human subjects.
STATINS AND CHOLESTEROL
DEPLETING AGENTS
Statins have been described as the most effective class of drugs
to reduce serum cholesterol levels (Oesterle et al., 2017). The
HMG-CoA reductase inhibitor fluvastatin inhibited the activity
of heterologously expressed human P2X4 and native P2X4 in
human monocytes (Li and Fountain, 2012). The activity of
fluvastatin is likely to be due to depletion of cellular cholesterol
as its inhibitory action was mimicked by methyl-β-cyclodextrin
and filipin III (Li and Fountain, 2012). Some further studies
have shown association of P2X4 within lipid rafts (Allsopp et al.,
2010).
RECENT ADVANCES IN P2X4
PHARMACOLOGICAL AGENTS
Research surrounding P2X4 has been greatly hindered due to the
lack of selective receptor antagonists. For a long time, researchers
had to rely on non-selective P2X receptor antagonists such
as TNP-ATP, BBG and paroxetine to study P2X4. However,
these agents possess low affinity for P2X4 and are significantly
more potent at other targets. Recently growing evidence that
highlights the importance of P2X4 in health and disease has
triggered interest in the development of selective receptor
antagonists (Table 1). The discovery of selective P2X4 antagonists
will, therefore, present a new avenue for scientific research to
selectively target P2X4 therapeutically.
5-BDBD
The benzodiazepine derivative 5-BDBD (5-(3-bromophenyl)-
1,3-dihydro-2H-benzofuro[3,2-e]-1,4-diazepin-2-one) was one
of the first selective P2X4 antagonists to be described in the
literature (Balazs et al., 2013). The original experimental details
are documented in a patent (Fischer et al., 2005), however,
5-BDBD is now commercially available. This compound has been
reported as a moderately potent and selective P2X4 antagonist
with an IC50 value of 1.2 µM in HEK-293 cells expressing
human P2X4 (Balazs et al., 2013). The application of two
different concentrations of 5-BDBD resulted in a rightward shift
in ATP dose-response curve indicating that 5-BDBD acts as a
competitive antagonist to P2X4 (Balazs et al., 2013). However,
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radioligand binding assays illustrated that 5-BDBD was unable
to displace [35S]ATPγS binding to P2X4 indicating that rather
than acting as a true competitive antagonist, it has an allosteric
mechanism at P2X4 (Abdelrahman et al., 2016).
N-SUBSTITUTED PHENOXAZINE
DERIVATIVES
More recently, compounds derived from N-substituted
phenoxazine were identified as potent and selective allosteric
P2X4 antagonists (Hernandez-Olmos et al., 2012). One of the
derivatives, N-(Benzyloxycarbonyl) phenoxazine (PSB-12054), is
an extremely potent antagonist of the human P2X4 (IC50 value
of 0.189 µM), but is less potent toward rat P2X4 (IC50 value
of 2.1 µM) and mouse P2X4 (IC50 value of 1.77 µM). It has
been reported to possess high selectivity for human P2X4 with
over 50-fold against P2X2, P2X3 and P2X7 and over 30-fold
against P2X1 (Hernandez-Olmos et al., 2012). The second less
potent, but more water-soluble, of the two derivatives is N-(p-
methylphenylsulfonyl)phenoxazine (PSB-12062). PSB-12062 was
shown to have similar potency in all three species: human P2X4
(IC50 value of 1.38 µM), rat P2X4 (IC50 value of 0.928 µM)
and mouse P2X4 (IC50 value of 1.76 µM) (Hernandez-Olmos
et al., 2012). PSB-12062 has been shown to be allosteric in nature
with a 35-fold selectivity toward P2X4 versus P2X1, P2X2, P2X3,
and P2X7. However, PSB-12062 was unable to completely block
ATP-induced P2X4-mediated calcium influx even when used at
high concentrations (>30 µM) (Hernandez-Olmos et al., 2012).
A third compound also derived from N-substituted phenoxazine,
PSB-12253, was used in a study on HUVECs to investigate P2X4
responses. The effects of this selective antagonist were confirmed
by siRNA in HUVECs (Sathanoori et al., 2015).
CARBAMAZEPINE DERIVATIVES
Several carbamazepine derivatives were investigated as potential
P2X4 antagonists, with N,N-diisopropyl-5H-dibenz[b,f]azepine-
5-carboxamide being found to be the most potent toward human
P2X4 (IC50 of 3.44 µM) although less potent at mouse and rat
P2X4 (Tian et al., 2014). Despite its potency toward human P2X4,
it appeared to lack selectivity against two other P2X subtype
(P2X1 and P2X3) but was selective versus P2X2 and P2X7.
Further optimization will be required to improve the selectivity
of this compound.
BX430
One of the most recently discovered P2X4 antagonists is
the phenylurea BX430 (1-(2,6-dibromo-4-isopropyl-phenyl)-3-
(3-pyriudyl)urea which has been shown through a patch-clamp
study to have sub-micromolar potency (IC50 value of 0.54 µM)
and a 10 – 100 fold selectivity toward P2X4 versus other P2X
subtypes (Ase et al., 2015). Acting through a non-competitive
allosteric route, BX430 has been shown to be able to potently
antagonize zebrafish P2X4 but has no effect on rat and mouse
P2X4 orthologs (Ase et al., 2015). BX430 was seen to completely
abolish ivermectin facilitated pore formation and, according to
the authors, BX430 is the only known compound to inhibit P2X4
mediated pore formation (Ase et al., 2015).
NP-1815-PX
Screening a chemical library identified the compound NP-
1815-PX (5-[3-(5-thioxo-4H-[1,2,4]oxadiazol-3-yl)phenyl]-1H-
naphtho[1,2-b][1,4]diazepine-2,4(3H,5H)-dione) as a novel
human P2X4 antagonist (IC50 value of 0.26 µM) (Matsumura
et al., 2016). The inhibitory effect of NP-1815-PX was also
shown on rat and mouse P2X4 and it showed selectivity against
other P2X receptors (Matsumura et al., 2016). Intrathecal
administration of NP-1815-PX alleviated nerve damage-
associated mechanical allodynia in a chronic pain model and
in a herpetic pain model without altering acute pain sensing
(Matsumura et al., 2016).
FUTURE PERSPECTIVES
The discovery of new pharmacological tools, some of which are
now available commercially, will facilitate our understanding of
P2X4 cellular function in health and disease. In addition, such
tools may provide chemical scaffolds for the development of new
drugs that may be beneficial in the treatment of neuropathic
pain. P2X4-selective antagonists with high potency, no species-
restricted effect, water-solubility and, most importantly, an anti-
allodynia effect in rodent chronic pain models remain to be
identified.
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